DEVELOPMENT OF INNOVATIVE STRATEGIES AND THERAPEUTIC AGENTS (Q3189507): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): THIS PROJECT AIMS AT THE SYNTHESIS OF NEW PHARMACOS AND THE DEVELOPMENT OF INNOVATIVE METHODOLOGIES TO HELP IMPROVE CURRENT THERAPIES FOR THE TREATMENT OF SOME OF THE MOST COMMON DISEASES TODAY. EFFORTS ARE MAINLY FOCUSED ON THE DISCOVERY OF NEW ANTITUMOR AGENTS, ANTIVIRAL AGENTS, ANTIMALARIAL AGENTS AND FOR THE TREATMENT OF NEURAL DYSFUNCTIONS, SINCE CANCER, VIRIC DISEASES (ESPECIALLY HIV AND HSV), MALARIA AND NEURODEGENERATIVE DISORDERS (AND I...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
DEVELOPMENT OF INNOVATIVE STRATEGIES AND THERAPEUTIC AGENTS | |||
Revision as of 21:11, 12 October 2021
Project Q3189507 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF INNOVATIVE STRATEGIES AND THERAPEUTIC AGENTS |
Project Q3189507 in Spain |
Statements
52,635.0 Euro
0 references
105,270.0 Euro
0 references
50.0 percent
0 references
30 December 2016
0 references
31 December 2020
0 references
UNIVERSIDAD AUTONOMA DE BARCELONA
0 references
41°29'27.71"N, 2°8'15.00"E
0 references
08266
0 references
ESTE PROYECTO PERSIGUE LA SINTESIS DE NUEVOS FARMACOS Y EL DESARROLLO DE METODOLOGIAS INNOVADORAS QUE AYUDEN A MEJORAR LAS TERAPIAS ACTUALES PARA EL TRATAMIENTO DE ALGUNAS DE LAS ENFERMEDADES MAS FRECUENTES EN LA ACTUALIDAD. LOS ESFUERZOS SE FOCALIZAN FUNDAMENTALMENTE EN EL DESCUBRIMIENTO DE NUEVOS AGENTES ANTITUMORALES, ANTIVIRICOS, ANTIMALARICOS Y PARA EL TRATAMIENTO DE DISFUNCIONES NEURONALES, DADO QUE EL CANCER, LAS ENFERMEDADES VIRICAS (ESPECIALMENTE VIH Y VHS), LA MALARIA Y LOS TRASTORNOS NEURODEGENERATIVOS (Y EN PARTICULAR LA ENFERMEDAD DE PARKINSON) FIGURAN ENTRE LAS DOLENCIAS DE MAYOR INCIDENCIA EN LA POBLACION. SE COMBINA LA SINTESIS DE NUEVOS CANDIDATOS A FARMACOS CON EL DESARROLLO DE NUEVAS NANOPARTICULAS, COMO PLATAFORMAS PARA LA ENCAPSULACION DE LOS PRINCIPIOS ACTIVOS Y SU TRANSPORTE Y LIBERACION EN EL ORGANISMO DE FORMA CONTROLADA, Y EL ESTUDIO DE METODOLOGIAS QUE PERMITAN LA ACTIVACION IN SITU DE LOS AGENTES TERAPEUTICOS. LOS CANDIDATOS A AGENTES ANTITUMORALES QUE SE PRETENDE SINTETIZAR Y EVALUAR SON CICLOHEXENOIDES C7 POLIOXIGENADOS (ANALOGOS DEL SHIKIMATO) Y COMPLEJOS DE PLATINO (ANALOGOS DEL CISPLATINO) SUSCEPTIBLES DE SER UTILIZADOS EN UNA TERAPIA DE FOTOACTIVACION (PACT) NOVEDOSA, DONDE SE BUSCA LA MODIFICACION DE LA GEOMETRIA DEL COMPLEJO MEDIANTE FOTOACTIVACION DEL LIGANDO. SE DETERMINARA LA CAPACIDAD DE INTERCALACION EN EL ADN DE ESTOS COMPUESTOS Y SE INTENTARA RELACIONARLA CON SU ACTIVIDAD ANTITUMORAL. LOS CANDIDATOS ANTIVIRICOS CON PRESTACIONES MEJORADAS SON ANALOGOS CARBOCICLICOS DE NUCLEOSIDOS BASADOS EN ESTUDIOS DE MODELIZACION MOLECULAR Y DOCKING. POR OTRA PARTE, TANTO PARA ESTA TERAPIA ANTIVIRICA COMO PARA LA DEL PARKINSON, SE PLANTEA DESARROLLAR NANOPARTICULAS BASADAS EN COMPUESTOS CATECOL, METALORGANICAS O MERAMENTE POLIMERICAS, QUE PERMITAN CRUZAR LA BARRERA HEMATOENCEFALICA Y/O LA LIBERACION CONTROLADA DE COMBINACIONES DE LOS FARMACOS CORRESPONDIENTES. PARA EL CONTROL DE LA ACTIVIDAD NEURONAL SE HA OPTADO POR UNA APROXIMACION BASADA EN LA OPTOFARMACOLOGIA. SE UTILIZARAN MOLECULAS QUE ACTUEN COMO INTERRUPTORES MOLECULARES CAPACES DE CONTROLAR, MEDIANTE IRRADIACION EXTERNA EN EL NIR, EL FUNCIONAMIENTO DE LOS RECEPTORES IONOTROPICOS DE GLUTAMATO PRESENTES EN LAS CELULAS DEL SISTEMA NERVIOSO CENTRAL. SE PREPARARAN LIGANDOS FOTOCROMICOS ANCLADOS, CON NUCLEOS AZOBENCENICOS, Y LIGANDOS FOTOCROMICOS, CON NUCLEOS ESTILBENICOS, AMBOS OPERATIVOS BAJO IRRADIACION NIR, Y SE ENSAYARA SU ACTIVIDAD IN VITRO. LOS ANTIMALARICOS SE BASAN EN ESTRUCTURAS DE TIPO 4-AMINOQUINOLINA, FUNCIONALIZADAS CON UNIDADES DE QUINOLICIDINA E INDOLICIDINA, Y PERSIGUEN ENCONTRAR UNA ALTERNATIVA A LA CLOROQUINA, FARMACO PARA EL QUE SE HA DESCRITO LA APARICION DE CEPAS RESISTENTES, UN PROBLEMA DE ESPECIAL RELEVANCIA EN LAS ENFERMEDADES CRONICAS. (Spanish)
0 references
THIS PROJECT AIMS AT THE SYNTHESIS OF NEW PHARMACOS AND THE DEVELOPMENT OF INNOVATIVE METHODOLOGIES TO HELP IMPROVE CURRENT THERAPIES FOR THE TREATMENT OF SOME OF THE MOST COMMON DISEASES TODAY. EFFORTS ARE MAINLY FOCUSED ON THE DISCOVERY OF NEW ANTITUMOR AGENTS, ANTIVIRAL AGENTS, ANTIMALARIAL AGENTS AND FOR THE TREATMENT OF NEURAL DYSFUNCTIONS, SINCE CANCER, VIRIC DISEASES (ESPECIALLY HIV AND HSV), MALARIA AND NEURODEGENERATIVE DISORDERS (AND IN PARTICULAR PARKINSON’S DISEASE) ARE AMONG THE MOST COMMON DISEASES IN THE POPULATION. IT COMBINES THE SYNTHESIS OF NEW CANDIDATES FOR PHARMACOLOGY WITH THE DEVELOPMENT OF NEW NANOPARTICULAE, AS PLATFORMS FOR THE ENCAPSULATION OF THE ACTIVE SUBSTANCES AND THEIR TRANSPORT AND RELEASE IN THE ORGANISM IN A CONTROLLED WAY, AND THE STUDY OF METHODS THAT ALLOW THE IN SITU ACTIVATION OF THE THERAPEUTIC AGENTS. THE CANDIDATES FOR ANTITUMOR AGENTS THAT ARE INTENDED TO BE SYNTHESISED AND EVALUATED ARE CYCLOHEXENOIDS C7 POLIOXIGENADOS (SHIKIMATO ANALOGS) AND PLATINUM COMPLEXES (CISPLATIN ANALOGUES) THAT MAY BE USED IN A NOVEL PHOTOACTIVACION (PACT) THERAPY, WHERE THE MODIFICATION OF THE COMPLEX’S GEOMETRIA IS SOUGHT BY MEANS OF FOTOACTIVACION OF THE LIGAND. THE CAPACITY OF INTERCALACION IN THE DNA OF THESE COMPOUNDS WILL BE DETERMINED AND ATTEMPTED TO RELATE TO THEIR ANTITUMOR ACTIVITY. ANTIVIRAL CANDIDATES WITH IMPROVED PERFORMANCE ARE NUCLEOSIDE CARBOCICLICS ANALOGS BASED ON MOLECULAR MODELLING AND DOCKING STUDIES. ON THE OTHER HAND, FOR BOTH THIS ANTIVIRICA AND PARKINSON’S THERAPY, IT IS PROPOSED TO DEVELOP NANOPARTICULAE BASED ON CATECOL COMPOUNDS, METALORGANICAS OR MERELY POLYMERIC, THAT ALLOW CROSSING THE BLOOD-BRAIN BARRIER AND/OR THE CONTROLLED RELEASE OF COMBINATIONS OF THE CORRESPONDING PHARMACOS. FOR THE CONTROL OF NEURONAL ACTIVITY, AN APPROACH BASED ON OPTOPHARMACOLOGY HAS BEEN CHOSEN. MOLECULES THAT ACT AS MOLECULAR SWITCHES CAPABLE OF CONTROLLING, BY EXTERNAL IRRADIATION IN THE NIR, THE FUNCTIONING OF THE GLUTAMATE IONOTROPIC RECEPTORS PRESENT IN CENTRAL NERVOUS SYSTEM CELLS SHALL BE USED. ANCHORED PHOTOCROMIC LIGANDS, WITH AZOBENCENIC NUCLEI, AND PHOTOCROMIC LIGANDS, WITH STILBENIC NUCLEI, BOTH OPERATIONS UNDER NIR IRRADIATION, WILL BE PREPARED AND TESTED FOR IN VITRO ACTIVITY. ANTIMALARICS ARE BASED ON 4-AMINOQUINOLINE TYPE STRUCTURES, FUNCTIONALISED WITH QUINOLICIDIN AND INDOLICIDIN UNITS, AND SEEK TO FIND AN ALTERNATIVE TO CHLOROQUINE, A PHARMACO FOR WHICH THE APPEARANCE OF RESISTANT STRAINS HAS BEEN DESCRIBED, A PROBLEM OF PARTICULAR RELEVANCE IN CHRONIC DISEASES. (English)
12 October 2021
0 references
Cerdanyola del Vallès
0 references
Identifiers
CTQ2016-75363-R
0 references